Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy

Anja Lorch, Jörg Beyer, Andrew Kramar, Lawrence Einhorn, Andrea Necchi, Christophe Massard, Ugo De Giorgi, Aude Flechon, Kim A. Margolin, Jean Pierre Lotz, Jose Ramon Lluch Germa, Thomas Powles, Christian K. Kollmannsberger, Caroline Bascoul-Mollevi

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Purpose: To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Patients and Methods: Data from 1,984 patients with GCT who progressed after at least three cisplatin-based cycles and were treated with cisplatin-based conventional-dose or carboplatin-based high-dose salvage chemotherapy was retrospectively collected from 38 centers/groups worldwide. One thousand five hundred ninety-four (80%) of 1,984 eligible patients were randomly divided into a training set of 1,067 patients (67%) and a validation set of 527 patients (33%). Seminomas were set aside for posthoc analyses. Primary end point was the 2-year progression-free survival after salvage treatment. Results: Overall, 990 patients (62%) relapsed and 604 patients (38%) remained relapse free. Histology, primary tumor location, response, and progression-free interval after first-line treatment, as well as levels of alpha fetoprotein, human chorionic gonadotrophin, and the presence of liver, bone, or brain metastases at salvage were identified as independent prognostic variables and used to build a prognostic model in the training set. Survival rates in the training and validation set were very similar. The estimated 2-year progression-free survival rates in patients not included in the training set was 75% in very low risk, 51% in low risk, 40% in intermediate risk, 26% in high risk, and only 6% in very high-risk patients. Due to missing values in individual variables, 69 patients could not reliably be classified into one of these categories. Conclusion: Prognostic variables are important in patients with GCT who experienced treatment failure with cisplatin-based first-line chemotherapy and can be used to construct a prognostic model to guide salvage strategies.

Original languageEnglish (US)
Pages (from-to)4906-4911
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number33
DOIs
StatePublished - Nov 20 2010
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Treatment Failure
Cisplatin
Drug Therapy
Disease-Free Survival
Survival Rate
Salvage Therapy
Seminoma
Carboplatin
alpha-Fetoproteins
Chorionic Gonadotropin
Histology
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. / Lorch, Anja; Beyer, Jörg; Kramar, Andrew; Einhorn, Lawrence; Necchi, Andrea; Massard, Christophe; De Giorgi, Ugo; Flechon, Aude; Margolin, Kim A.; Lotz, Jean Pierre; Germa, Jose Ramon Lluch; Powles, Thomas; Kollmannsberger, Christian K.; Bascoul-Mollevi, Caroline.

In: Journal of Clinical Oncology, Vol. 28, No. 33, 20.11.2010, p. 4906-4911.

Research output: Contribution to journalArticle

Lorch, A, Beyer, J, Kramar, A, Einhorn, L, Necchi, A, Massard, C, De Giorgi, U, Flechon, A, Margolin, KA, Lotz, JP, Germa, JRL, Powles, T, Kollmannsberger, CK & Bascoul-Mollevi, C 2010, 'Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy', Journal of Clinical Oncology, vol. 28, no. 33, pp. 4906-4911. https://doi.org/10.1200/JCO.2009.26.8128
Lorch, Anja ; Beyer, Jörg ; Kramar, Andrew ; Einhorn, Lawrence ; Necchi, Andrea ; Massard, Christophe ; De Giorgi, Ugo ; Flechon, Aude ; Margolin, Kim A. ; Lotz, Jean Pierre ; Germa, Jose Ramon Lluch ; Powles, Thomas ; Kollmannsberger, Christian K. ; Bascoul-Mollevi, Caroline. / Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 33. pp. 4906-4911.
@article{4a42e33856244b2fa9ff9723f7d350e2,
title = "Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy",
abstract = "Purpose: To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Patients and Methods: Data from 1,984 patients with GCT who progressed after at least three cisplatin-based cycles and were treated with cisplatin-based conventional-dose or carboplatin-based high-dose salvage chemotherapy was retrospectively collected from 38 centers/groups worldwide. One thousand five hundred ninety-four (80{\%}) of 1,984 eligible patients were randomly divided into a training set of 1,067 patients (67{\%}) and a validation set of 527 patients (33{\%}). Seminomas were set aside for posthoc analyses. Primary end point was the 2-year progression-free survival after salvage treatment. Results: Overall, 990 patients (62{\%}) relapsed and 604 patients (38{\%}) remained relapse free. Histology, primary tumor location, response, and progression-free interval after first-line treatment, as well as levels of alpha fetoprotein, human chorionic gonadotrophin, and the presence of liver, bone, or brain metastases at salvage were identified as independent prognostic variables and used to build a prognostic model in the training set. Survival rates in the training and validation set were very similar. The estimated 2-year progression-free survival rates in patients not included in the training set was 75{\%} in very low risk, 51{\%} in low risk, 40{\%} in intermediate risk, 26{\%} in high risk, and only 6{\%} in very high-risk patients. Due to missing values in individual variables, 69 patients could not reliably be classified into one of these categories. Conclusion: Prognostic variables are important in patients with GCT who experienced treatment failure with cisplatin-based first-line chemotherapy and can be used to construct a prognostic model to guide salvage strategies.",
author = "Anja Lorch and J{\"o}rg Beyer and Andrew Kramar and Lawrence Einhorn and Andrea Necchi and Christophe Massard and {De Giorgi}, Ugo and Aude Flechon and Margolin, {Kim A.} and Lotz, {Jean Pierre} and Germa, {Jose Ramon Lluch} and Thomas Powles and Kollmannsberger, {Christian K.} and Caroline Bascoul-Mollevi",
year = "2010",
month = "11",
day = "20",
doi = "10.1200/JCO.2009.26.8128",
language = "English (US)",
volume = "28",
pages = "4906--4911",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy

AU - Lorch, Anja

AU - Beyer, Jörg

AU - Kramar, Andrew

AU - Einhorn, Lawrence

AU - Necchi, Andrea

AU - Massard, Christophe

AU - De Giorgi, Ugo

AU - Flechon, Aude

AU - Margolin, Kim A.

AU - Lotz, Jean Pierre

AU - Germa, Jose Ramon Lluch

AU - Powles, Thomas

AU - Kollmannsberger, Christian K.

AU - Bascoul-Mollevi, Caroline

PY - 2010/11/20

Y1 - 2010/11/20

N2 - Purpose: To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Patients and Methods: Data from 1,984 patients with GCT who progressed after at least three cisplatin-based cycles and were treated with cisplatin-based conventional-dose or carboplatin-based high-dose salvage chemotherapy was retrospectively collected from 38 centers/groups worldwide. One thousand five hundred ninety-four (80%) of 1,984 eligible patients were randomly divided into a training set of 1,067 patients (67%) and a validation set of 527 patients (33%). Seminomas were set aside for posthoc analyses. Primary end point was the 2-year progression-free survival after salvage treatment. Results: Overall, 990 patients (62%) relapsed and 604 patients (38%) remained relapse free. Histology, primary tumor location, response, and progression-free interval after first-line treatment, as well as levels of alpha fetoprotein, human chorionic gonadotrophin, and the presence of liver, bone, or brain metastases at salvage were identified as independent prognostic variables and used to build a prognostic model in the training set. Survival rates in the training and validation set were very similar. The estimated 2-year progression-free survival rates in patients not included in the training set was 75% in very low risk, 51% in low risk, 40% in intermediate risk, 26% in high risk, and only 6% in very high-risk patients. Due to missing values in individual variables, 69 patients could not reliably be classified into one of these categories. Conclusion: Prognostic variables are important in patients with GCT who experienced treatment failure with cisplatin-based first-line chemotherapy and can be used to construct a prognostic model to guide salvage strategies.

AB - Purpose: To develop a prognostic model in patients with germ cell tumors (GCT) who experience treatment failure with cisplatin-based first-line chemotherapy. Patients and Methods: Data from 1,984 patients with GCT who progressed after at least three cisplatin-based cycles and were treated with cisplatin-based conventional-dose or carboplatin-based high-dose salvage chemotherapy was retrospectively collected from 38 centers/groups worldwide. One thousand five hundred ninety-four (80%) of 1,984 eligible patients were randomly divided into a training set of 1,067 patients (67%) and a validation set of 527 patients (33%). Seminomas were set aside for posthoc analyses. Primary end point was the 2-year progression-free survival after salvage treatment. Results: Overall, 990 patients (62%) relapsed and 604 patients (38%) remained relapse free. Histology, primary tumor location, response, and progression-free interval after first-line treatment, as well as levels of alpha fetoprotein, human chorionic gonadotrophin, and the presence of liver, bone, or brain metastases at salvage were identified as independent prognostic variables and used to build a prognostic model in the training set. Survival rates in the training and validation set were very similar. The estimated 2-year progression-free survival rates in patients not included in the training set was 75% in very low risk, 51% in low risk, 40% in intermediate risk, 26% in high risk, and only 6% in very high-risk patients. Due to missing values in individual variables, 69 patients could not reliably be classified into one of these categories. Conclusion: Prognostic variables are important in patients with GCT who experienced treatment failure with cisplatin-based first-line chemotherapy and can be used to construct a prognostic model to guide salvage strategies.

UR - http://www.scopus.com/inward/record.url?scp=84878708632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878708632&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.26.8128

DO - 10.1200/JCO.2009.26.8128

M3 - Article

VL - 28

SP - 4906

EP - 4911

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -